INS and diabetic kidney disease: In the AWARD-7 trial for example, dulaglutide compared to insulin treatment resulted in similar effects on HbA1c but reduced the rate of eGFR decline and the risk of ESKD in patients with diabetic kidney disease (Tuttle et al., 2018).